New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
07:46 EDTMDRXAllscripts price target lowered to $11 from $16 at RW Baird
Baird lowered its price target on Allscripts following its announcement management has concluded its exploration of strategic alternatives that did not produce a sale or merger of the company. The firm removed the takeout premium and believes investors should view the company as a long term investment with a conservative valuation. Shares remain Outperform rated.
News For MDRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
08:20 EDTMDRXAllscripts takes $200M equity position in NantHealth
Allscripts announced they have taken a significant step forward in their strategic partnership through two cross-investments and a strengthening of their commercial agreement. The investments include Allscripts' purchase of a 10% equity stake in NantHealth for $200M in cash. In addition, NantCapital, LLC, the personal investment vehicle of Dr. Patrick Soon-Shiong, founder of NantHealth, has made a $100M investment into Allscripts.
June 24, 2015
08:27 EDTMDRXAllscripts management to meet with Evercore ISI
Subscribe for More Information
June 18, 2015
10:01 EDTMDRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
June 17, 2015
16:19 EDTMDRXAllscripts initiated with a Perform at Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use